- Home
- PRME vs TALK Comparison
PRME vs TALK Comparison
Compare PRME & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | TALK |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | 521 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 788.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRME | TALK |
|---|---|---|
| Price | $3.56 | $5.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $7.56 | $6.42 |
| AVG Volume (30 Days) | 2.6M | ★ 5.8M |
| Earning Date | 03-03-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $15.20 | $26.02 |
| Revenue Next Year | $316.23 | $21.24 |
| P/E Ratio | ★ N/A | $155.55 |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.11 | $2.22 |
| 52 Week High | $6.94 | $5.19 |
Technical Indicators
Market Signals| Indicator | PRME | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 66.17 |
| Support Level | $3.19 | $4.59 |
| Resistance Level | $4.74 | $5.19 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 9.46 | 90.02 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.